Omeros Corporation (NASDAQ:OMER)‘s stock had its “buy” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research note issued on Monday. They presently have a $21.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 180.00% from the stock’s current price.
A number of other research analysts have also commented on OMER. Maxim Group reiterated a “buy” rating and set a $30.00 price target on shares of Omeros Corporation in a report on Thursday, July 28th. S&P Equity Research upped their target price on Omeros Corporation from $7.65 to $8.63 in a research note on Monday. WBB Securities restated a “buy” rating and issued a $75.00 target price on shares of Omeros Corporation in a research note on Monday. Wedbush restated an “outperform” rating and issued a $56.00 target price (down from $62.00) on shares of Omeros Corporation in a research note on Thursday, August 11th. Finally, Zacks Investment Research lowered Omeros Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, July 13th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $32.45.
Shares of Omeros Corporation (NASDAQ:OMER) opened at 7.50 on Monday. The company’s 50 day moving average is $10.41 and its 200-day moving average is $11.57. The company’s market capitalization is $294.70 million. Omeros Corporation has a 52 week low of $7.20 and a 52 week high of $16.80.
Omeros Corporation (NASDAQ:OMER) last issued its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.18. The business had revenue of $10 million for the quarter, compared to analyst estimates of $9.80 million. During the same quarter last year, the firm earned ($0.44) earnings per share. The firm’s quarterly revenue was up 212.5% compared to the same quarter last year. On average, analysts expect that Omeros Corporation will post ($1.55) EPS for the current fiscal year.
In other Omeros Corporation news, VP Marcia S. Kelbon sold 15,900 shares of the company’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $11.56, for a total value of $183,804.00. Following the sale, the vice president now directly owns 179,497 shares in the company, valued at $2,074,985.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Marcia S. Kelbon sold 16,000 shares of the company’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $10.91, for a total value of $174,560.00. Following the completion of the sale, the vice president now owns 179,597 shares in the company, valued at $1,959,403.27. The disclosure for this sale can be found here. 13.60% of the stock is owned by company insiders.
Hedge funds have recently made changes to their positions in the stock. Sheaff Brock Investment Advisors LLC bought a new stake in shares of Omeros Corporation during the second quarter worth $105,000. Bourgeon Capital Management LLC bought a new stake in shares of Omeros Corporation during the second quarter worth $158,000. BlackRock Advisors LLC boosted its stake in shares of Omeros Corporation by 1.0% in the second quarter. BlackRock Advisors LLC now owns 17,415 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 173 shares during the last quarter. Mesirow Financial Investment Management Equity Management acquired a new stake in shares of Omeros Corporation during the second quarter valued at approximately $244,000. Finally, Gradient Investments LLC boosted its stake in shares of Omeros Corporation by 3.3% in the third quarter. Gradient Investments LLC now owns 25,285 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 814 shares during the last quarter. Hedge funds and other institutional investors own 48.04% of the company’s stock.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.